This is the bit I liked......
In 2018 significant new clinical data was generated with our lead product candidate eftilagimod alpha(“efti”), particularly from our Phase I TACTI-mel clinical trial. 2019 promises to be a very data heavy yearfor Immutep, with multiple value enhancing clinical data sets expected.
I detected a note of confidence there, Marc would have one eye on the trials and I doubt he would say that
if there were any issues with them...
I:E......if you take "value enhancing" out of that sentence it would still make sense...
Take that how you wish but I simply can't fathom why it would be said if it wasn't a distinct possibility...
Ann: Immutep Investor Update, page-5
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.010(3.51%) |
Mkt cap ! $400.0M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.3¢ | 27.0¢ | $1.034M | 3.758M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 98156 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 85523 | 9 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |